Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5770010

CCOc1ccccc1N1CCN(C(=O)CCc2cnoc2-c2ccc(F)cc2)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.49
HTR7 P34969 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 4/20 0.46
NLRP1 Q9C000 1/20 0.46
NPSR1 Q6W5P4 4/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 2/20 0.43
APAF1 O14727 1/20 0.43
TACR1 P25103 1/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5777370 0.92 L3MBTL1 (0.55) HTR7L3MBTL1MAPTPOLBMEN1
Trifluoroacetic Acid SCHEMBL5775195 0.88 ATM (0.49) L3MBTL1MAPTKMT2A
Trifluoroacetic Acid SCHEMBL5775321 0.88 KMT2A (0.53) L3MBTL1MAPTPOLBMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5776836 0.88 PARP1 (0.44) HTR7L3MBTL1MAPTMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5772610 0.85 GFER (0.53) MAPTNPSR1POLBMEN1KMT2A
Trifluoroacetic Acid SCHEMBL5776691 0.84 GRM5 (0.48) HTR1AHTR7L3MBTL1MAPTPOLB
Trifluoroacetic Acid SCHEMBL5777433 0.84 GFER (0.53) MAPTPOLBMEN1KMT2ATSHR
Trifluoroacetic Acid SCHEMBL5774748 0.83 ALDH1A1 (0.53) HTR7L3MBTL1KMT2ASMN1; SMN2TSHR
Trifluoroacetic Acid SCHEMBL5776847 0.83 MDM2 (0.39) HTR1AHTR7L3MBTL1MAPTMEN1
Trifluoroacetic Acid SCHEMBL5776834 0.83 HTT (0.46) HTR1AHTR7MAPTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160324823-A1 TREATMENT OF MITOCHONDRIAL DISEASES BIOELECTRON TECHNOLOGY CORPORATION 2016-11-10 US claimed
US-20130267538-A1 TREATMENT OF MITOCHONDRIAL DISEASES GALILEO PHARMACEUTICALS INC. 2013-10-10 US claimed
WO-2005032544-A1 TREATMENT OF MITOCHONDRIAL DISEASES GALILEO PHARMACEUTICALS, INC. (US) 2005-04-14 WO claimed
US-20050065099-A1 Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects EDISON PHARMACEUTICALS, INC. 2005-03-24 US claimed
US-20160324823-A1 TREATMENT OF MITOCHONDRIAL DISEASES BIOELECTRON TECHNOLOGY CORPORATION 2016-11-10 US disclosed
US-20130267538-A1 TREATMENT OF MITOCHONDRIAL DISEASES GALILEO PHARMACEUTICALS INC. 2013-10-10 US disclosed
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
WO-2005032544-A1 TREATMENT OF MITOCHONDRIAL DISEASES GALILEO PHARMACEUTICALS, INC. (US) 2005-04-14 WO disclosed
US-20050065099-A1 Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects EDISON PHARMACEUTICALS, INC. 2005-03-24 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065099-A1 Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects CLN6, LDHA, NLN HTR1A 928/4885HTR7 2820/4885L3MBTL1 512/4885
US-20160324823-A1 TREATMENT OF MITOCHONDRIAL DISEASES NLN, FH, MFN2 HTR1A 1006/4885HTR7 2629/4885L3MBTL1 842/4885
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR HTR1A 2719/4885HTR7 1306/4885L3MBTL1 2718/4885
US-20130267538-A1 TREATMENT OF MITOCHONDRIAL DISEASES NLN, FH, MFN2 HTR1A 1006/4885HTR7 2629/4885L3MBTL1 842/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 HTR1A 1650/4885HTR7 1109/4885L3MBTL1 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.